Form 4: Silexion Director Acquires Shares & Options Amid Splits

Silexion Therapeutics Corp director Avner Lushi indirectly acquired ordinary shares and stock options through Guangzhou Sino-Israel Biotech Fund, with holdings adjusted for recent reverse stock splits.

Summary

• Avner Lushi, a Director and 10% Owner of Silexion Therapeutics Corp (SLXN), indirectly acquired 1,587 ordinary shares and 1,872 stock options on February 9, 2025.
• The acquisition was made through Guangzhou Sino-Israel Biotech Fund (GIBF), where Mr. Lushi serves as a Managing Partner and CEO, possessing shared voting and investment authority.
• The 1,587 ordinary shares represent Restricted Stock Units (RSUs) granted for director services provided by Mr. Lushi and Shlomo Noy, vesting in full on February 9, 2026.
• The 1,872 stock options, with an exercise price of $18.9, were also granted for director services provided by Mr. Lushi and Shlomo Noy, vesting and becoming exercisable on February 9, 2026, and expiring on February 9, 2035.
• All reported share and option amounts, as well as the option exercise price, have been retroactively adjusted to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
• An additional 14,721 ordinary shares are reported for informational purposes, with no transaction occurring, and these holdings have been adjusted for both a 1-for-9 reverse share split on November 29, 2024, and the 1-for-15 reverse share split on July 29, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to a director and significant owner acquiring equity, signaling potential confidence. However, this is tempered by the negative implications of recent reverse stock splits, which often indicate underlying challenges.

Positives

• A director and significant owner acquiring shares and options, even if for services, can signal management's alignment with shareholder interests and confidence in the company's future.
• The grants of RSUs and stock options serve as a form of long-term incentive for director services, potentially encouraging sustained engagement and performance.

Negatives

• The company has undergone two significant reverse stock splits (1-for-9 on November 29, 2024, and 1-for-15 on July 29, 2025), which often indicate a low share price and can be perceived negatively by the market, potentially signaling underlying operational or financial challenges.
• Reverse splits can lead to reduced liquidity and may not address the fundamental reasons for a low stock price, potentially eroding investor confidence.

Risks

• The occurrence of two reverse stock splits within a short period (November 2024 and July 2025) highlights significant challenges in maintaining a desirable share price, which could impact investor perception and the company's ability to attract capital.
• The disclaiming of beneficial ownership by Mr. Lushi, except to the extent of his indirect pecuniary interest in GIBF, introduces complexity regarding the direct alignment of his personal financial interests with the company's performance.

Future Outlook

The acquired RSUs and stock options are scheduled to vest and become exercisable on February 9, 2026, contingent on continued service. The stock options have an expiration date of February 9, 2035.

Management Comments

• Avner Lushi, as a Managing Partner and CEO of Guangzhou Sino-Israel Biotech Fund (GIBF), possesses shared voting and investment authority over the reported securities.
• Mr. Lushi disclaims beneficial ownership of the securities reported except to the extent of his indirect pecuniary interest therein.

Industry Context

This Form 4 filing primarily details an insider transaction related to director compensation and beneficial ownership. While not directly tied to broader industry trends, the reverse stock splits are a notable event. In the biotech sector, companies sometimes execute reverse splits to meet listing requirements or improve stock perception, especially if their share price has fallen significantly.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of ordinary shares and stock options by Avner Lushi was made indirectly through Guangzhou Sino-Israel Biotech Fund (GIBF). Mr. Lushi is a Managing Partner and CEO of GIBF, establishing a related party relationship for these transactions.

Stakeholder Impact

• Shareholders: The acquisition of shares and options by a director and 10% owner may be viewed as a positive signal of alignment, but the recent reverse stock splits could raise concerns about share value and company stability.
• Management: The grants of RSUs and stock options serve as compensation and long-term incentives for director services, aligning management's interests with company performance.

Next Steps

• The 1,587 ordinary shares (RSUs) are expected to vest on February 9, 2026.
• The 1,872 stock options are expected to become exercisable on February 9, 2026.

Key Dates

Keywords

Silexion Therapeutics, SLXN, Form 4, Insider Transaction, Beneficial Ownership, Stock Options, RSUs, Reverse Stock Split, Director Compensation, Corporate Governance